A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-07976016 AND PF-06882961 IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity.
The total number of weeks of the study is up to approximately 22 weeks (5.5 months).

Start Date13 Mar 2025

Sponsor / Collaborator

Pfizer Inc.

NCT06541678

/ CompletedPhase 1

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Itraconazole and Cyclosporine on the Single-Dose Pharmacokinetics of Danuglipron in Healthy Adult Participants

The purpose of this study is to see how single dose of cyclosporine and multiple doses of itraconazole affect the level of the study medicine danuglipron in the blood of healthy adult participants. The information from this study may inform how danuglipron will be used in the future with medicines like cyclosporine and itraconazole.

Start Date23 Dec 2024

Sponsor / Collaborator

Pfizer Inc.

NCT06567327

/ CompletedPhase 1

A Two-Part Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Multiple Dose Pharmacokinetics of Danuglipron Following Oral Administration and The Effects of Steady-State Danuglipron on the Pharmacokinetics of Single Oral Dose of Atorvastatin and Rosuvastatin in Otherwise Healthy Adult Participants With Overweight or Obesity

The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese:
* how the study medicine, danuglipron, is taken up into the blood
* if the study medicine, danuglipron, changes how the body processes other study medicines (Atorvastatin and Rosuvastatin)
* about the safety and tolerability of danuglipron
The study will take place in 4 Cohorts (groups). The total number of weeks of the study is about 23 (about 6 months) for Cohort 1 and 22 weeks (about 5.5 months) for Cohort 2, 21 weeks (about 5 months) for Cohort 3 and 20 weeks (about 5 months) for Cohort 4.

Start Date28 Aug 2024

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Danuglipron

100 Translational Medicine associated with Danuglipron

100 Patents (Medical) associated with Danuglipron

Literatures (Medical) associated with Danuglipron

01 Sep 2025·DIABETES OBESITY & METABOLISM

Efficacy and safety of danuglipron (PF‐06882961) in adults with obesity: A randomized, placebo‐controlled, dose‐ranging phase 2b study

Article

Author: Sherry, Nicole ; Halstead, Patricia ; Saxena, Aditi R. ; Matsuoka, Osamu ; Cobain, Sonia ; Fukushima, Yasushi ; Tsamandouras, Nikolaos ; Bays, Harold E. ; Buckeridge, Clare ; Gorman, Donal N.

Abstract:

Aims:

This randomized, double‐blind, placebo‐controlled Phase 2b study aimed to assess the efficacy, safety, and tolerability of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, in adults with obesity.

Materials and Methods:

Eligible participants (aged 18–75 years; with obesity, without diabetes) were randomized to receive danuglipron or placebo twice daily (BID) for 26 or 32 weeks. Danuglipron was escalated to doses of 40–200 mg BID in 1‐, 2‐, or 4‐week intervals. Assessments included body weight, waist circumference, and safety evaluations.

Results:

Overall, 628 participants were randomized; of 626 receiving study treatment (placebo, n = 90; danuglipron, n = 536), 39.3% completed treatment. Approximately 38% of participants discontinued treatment because of adverse events (AEs) and 22% discontinued for other reasons. The primary endpoint was the change in weight from baseline to the end of treatment; all danuglipron groups demonstrated statistically significant reductions with least squares mean percentage decreases from baseline ranging from −5.0% (90% confidence interval [CI] −6.8%, −3.2%) to −12.9% (90% CI −16.1%, −9.5%) relative to placebo. Danuglipron was considered safe. Consistent with the mechanism, the most frequently reported events were nausea and vomiting, and increased rates of gastrointestinal AEs were generally observed at higher doses. Most events were reported as mild, and no other dose‐related trends were observed in safety endpoints.

Conclusions:

In participants with obesity, danuglipron resulted in statistically significant and clinically meaningful reductions in body weight versus placebo over 26 or 32 weeks. The overall safety profile observed in this study was consistent with expectations for the mechanism, although discontinuation rates due to AEs were higher than anticipated across all treatment groups, including placebo.ClinicalTrials.gov identifier: NCT04707313.

03 May 2025·Journal of biomolecular structure & dynamics

Discovery of non-peptide GLP-1r natural agonists for enhancing coronary safety in type 2 diabetes patients

Article

Author: Iranshahi, Mehrdad ; Azimi, Sabikeh G. ; Sadeghi-Aliabadi, Hojjat ; Hadizadeh, Farzin ; Rajabian, Fatemeh ; Shakour, Neda ; Hoseinpoor, Saeideh

This study explores the computational discovery of non-peptide agonists targeting the Glucagon-Like Peptide-1 Receptor (GLP-1R) to enhance the safety of major coronary outcomes in individuals affected by Type 2 Diabetes. The objective is to identify novel compounds that can activate the GLP-1R pathway without the limitations associated with peptide agonists. Type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular disease (CVD) and mortality, which is attributed to the accumulation of fat in organs, including the heart. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are frequently used to manage T2DM and could potentially offer cardiovascular benefits. Therefore, this study examines non-peptide agonists of GLP-1R to improve coronary safety in type 2 diabetes patients. After rigorous assessments, two standout candidates were identified, with natural compound 12 emerging as the most promising. This study represents a notable advancement in enhancing the management of coronary outcomes among individuals with type 2 diabetes. The computational methodology employed successfully pinpointed potential GLP-1R natural agonists, providing optimism for the development of safer and more effective therapeutic interventions. Although computational methodologies have provided crucial insights, realizing the full potential of these compounds requires extensive experimental investigations, crucial in advancing therapeutic strategies for this critical patient population.

10 Apr 2025·JOURNAL OF MEDICINAL CHEMISTRY

Discovery of New Difluorocyclobutyl Derivatives as Effective Glucagon-Like Peptide-1 Receptor Agonists with Reduced hERG Inhibitory Activities

Article

Author: Zhang, Jinzhu ; Wang, Jianghai ; Shao, Shuai ; Zhong, Yongqing ; Wang, Guojian ; Huang, Yun ; Tang, Xinyi ; Ma, Zhongjun ; Ding, Wanjing ; Lou, Jinfang ; Li, Yuanyuan ; Miao, Lei ; Xu, Sicong ; Lei, Shaowei

Danuglipron (PF-06882961), a small-molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R) developed by Pfizer, has shown significant potential to reduce blood glucose levels and weight in patients with type 2 diabetes mellitus. However, it has moderate hERG inhibitory activities (IC₅₀ = 4.3 μM), potentially conferring a risk for cardiac toxicity. Here, we report a new class of difluorocyclobutyl derivatives that can be used to reduce the potential hERG inhibition caused by the piperidine ring of danuglipron. After in vitro and in vivo screening, compound 73 was found to be the most potent GLP-1R agonist, with an EC₅₀ of 0.048 nM. Furthermore, compound 73 showed preferable absorption and excellent β-arrestin pathway selectivity compared with danuglipron. In the glucose tolerance test, compound 73 effectively inhibited elevated blood glucose levels. These results indicate that compound 73 is a promising GLP-1R agonist.

News (Medical) associated with Danuglipron

23 Jun 2025

·www.biospace.com

Lilly Takes Victory Lap on Oral Weight Loss Drug as Analysts Spot Safety Crack

iStock, Golden Sikorka While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, analysts from William Blair worried that adverse events are not tapering off as expected. As industry watchers eagerly await Eli Lilly’s third quarter obesity data drop for the oral candidate orforglipron, type 2 diabetes data released at the American Diabetes Association has analysts reading the tea leaves for what to expect. In investor notes over the weekend and on Monday, one firm zeroed in on a signal that suggests adverse events are not tapering off over time as is the case with the GLP-1 drugs that have taken the world by storm. Meanwhile, others dubbed the safety data clean. Orforglipron was featured in a session on next-generation oral weight loss drugs at ADA on Saturday. While much of the data from the Phase III ACHIEVE-1 trial had previously been released , clinical investigators had more to say on liver enzymes and tolerability. The results were simultaneously published in The New England Journal of Medicine . Analysts had been worried about the potential of seeing liver enzyme elevations, which could have suggested damage to the organ. But that was not the case—in fact, liver markers actually decreased from baseline by about two to four points, Jefferies noted. Addressing liver enzymes during an investor event over the weekend, Lilly’s management said the FDA is actually pushing companies to include patients with higher baseline liver enzymes to better match the typical patient population. Patients who had higher levels at the start of the trial did not experience elevations, according to the company. All these patients stayed on the study drug and their enzymes normalized or returned to baseline during the trial. “Overall, orfo has a clean pro detailed events of interest showed no real concerns, and [gastrointestinal] tolerability was deemed fine and numerically lower or in line with the injectables (except for diarrhea),” Jefferies wrote. Truist Securities spoke to key opinion leaders at ADA who still voiced concerns about liver enzymes, because the drug will likely be used for chronic weight management. Truist, however, said the concern is “likely overblown.” Leerink Partners similarly heralded the liver data as “clean.” But William Blair took issue with another part of the safety profile: gastrointestinal adverse events. While the firm believes orforglipron will “change practice in T2D,” obesity is a murkier indication, they contend. At the highest dose, nausea, vomiting and constipation did not appear to taper off as it typically does in patients taking GLP-1 drugs like Novo Nordisk’s semaglutide (marketed for weight loss as Wegovy) and Lilly’s own tirzepatide (Zepbound for weight loss), William Blair noted. “We are concerned by the persistence of both severe and frequent gastrointestinal adverse events beyond the titration period,” William Blair wrote. Truist, however, said the gastrointestinal side effects were mostly mild to moderate and mostly occurred during dose escalation as is typical of GLP-1s. The trial was designed to mitigate the symptoms after they were observed in the earlier Phase II trial. Patients in the orforglipron group discontinued the drug because of gastrointestinal side effects at a rate of 2.2% to 5.7%, depending on the dose arm. Truist said it’s notable that the highest dose had a dropout rate of under 6%, a “strong indication of the tolerability of the drug, in our view.” During a call with investors on Saturday, Lilly executives denied the characterization of diarrhea in the study as “persistent.” Jeff Emmick, senior vice president of product development, said there were geographic variabilities in the study, with higher rates of diarrhea seen in patients in India and China and extremely low rates in Japan. The U.S. was “midrange,” he added. The placebo groups in India and China also had fairly high rates of diarrhea, which Emmick said indicates differences in diet. He compared the gastrointestinal adverse events to that of tirzepatide. “Less than 6% at the highest dose discontinued due to a GI adverse event,” Emmick said. “If it had been such a big problem, [we] would have expected higher rates of discontinuation.” The Phase III ATTAIN trial is set to read out in the third quarter, which will finally give investors a glimpse at the weight loss data for orforglipron. Truist believes the diabetes data, which showed the drug significantly lowered blood sugar, has set up a positive readthrough to the obesity indication. The drug is easier to manufacture and for patients to take given it’s an oral, and they can take it without any food restrictions. Lilly plans to approval of orforglipron in obesity by the end of this year, followed by T2D in 2026. Emmick explained the rationale for filing for the weight management indication first. The FDA requires 24 months of exposure data for T2D, and only 18 for weight management. Therefore, since the trials started in parallel, the weight management data will be ready earlier. Lilly Still Believes in Triple G Lilly also used the ADA fanfare to tout its overall cardiometabolic pipeline during the call. Ken Custer, the newly minted president of cardiometabolic health at Lilly, told investors the company expects patient preference to dictate the future of the obesity market. “We fully expect the obesity market will segment into several logical categories based on things like the patient’s preferred route of administration, maybe less frequent dosing, tolerability, maybe a patient wants greater weight loss, different quality of weight loss,” Custer said. Besides weight management and diabetes, Lilly is also testing orforglipron in sleep apnea, similar to what was done with Zepbound. That drug earned a sleep apnea nod from the FDA in December 2024 . Lilly is also testing orforglipron for hypertension as well as examining maintenance dosing with the drug, including switching to the drug after injectables. One asset that caught the eye of BMO Capital Markets is the oral GLP-1 called naperiglipron, a triple G agonist that Lilly has said could unlock higher efficacy, according to BMO. But it uses the same “scaffold” as danuglipron, the failed obesity asset that Pfizer removed from its pipeline in April due to a case of drug-induced liver injury. BMO said Lilly’s continued interest shows the company’s “remaining belief in its potential.” “While history for the scaffold has been challenging, we are interested to learn more why Lilly believes it can evade these past pitfalls,” BMO wrote. If successful, naperiglipron could bring better efficacy in the oral class.

Phase 2Phase 3Clinical Result

21 Jun 2025

·firstwordpharma.com

ADA25: Lilly's oral GLP-1 dodges side effect minefield that sunk Pfizer drug

Eli Lilly detailed safety results for its oral GLP-1 asset orforglipron at the American Diabetes Association (ADA) meeting Saturday, highlighting the absence of liver toxicity, a problem that forced Pfizer to abandon its rival pill earlier this year."This convenient once-daily pill with no restrictions on food and water intake could be an option for millions of people with type 2 diabetes who prefer oral medications over injectables," said Jeff Emmick, Lilly's head of product development. "The positive ACHIEVE-1 results position orforglipron as a potential treatment option with meaningful A1C and weight reduction, and a safety profile similar to injectable GLP-1 therapies."The Phase III study is evaluating once-daily doses of orforglipron (3 mg, 12 mg, and 36 mg) as monotherapy in 559 adults with type 2 diabetes who have not achieved adequate glycaemic control through diet and exercise alone. Toplined earlier this year, patients taking orforglipron saw average reductions in HbA1c between 1.3% and 1.6% after 40 weeks, compared to just 0.1% for those on placebo, meeting the primary endpoint.On the key secondary endpoint of weight loss, patients receiving the 36-mg dose shed an average of 16 pounds, or up to 7.9% of their body weight. Lilly noted that weight loss did not appear to have plateaued by week 40, indicating the possibility for more reductions over time.Cardiometabolic gains"Beyond glycaemic control and bodyweight reduction, we observed reductions in cardiometabolic risk factors, including lipid levels, waist circumference, and systolic blood pressure, findings that indicate a favourable cardiovascular risk profile," researchers wrote in an NEJM paper, which was published Saturday.However, safety remains a central focus, with discontinuation rates and overall tolerability likely to serve as key measures for a therapy meant to be an option for chronic dosing.Lilly reiterated Saturday that orforglipron's overall safety profile in ACHIEVE-1 was consistent with the GLP-1 class as a whole, with gastrointestinal (GI) side effects such as diarrhoea (occurring in 19% to 26% of patients), nausea (13% to 18%), and dyspepsia (11% to 20%) being the most common. The events were generally mild-to-moderate and occurred mainly during dose escalation, researchers wrote.Gradual dosing escalationTo help minimise GI side effects seen in earlier studies, Lilly opted for a gradual dose-escalation strategy, starting with a lower dose and increasing every four weeks.Discontinuation rates due to side effects ranged from 4.4% to 7.8% across orforglipron doses, compared to 1.4% with placebo, and no cases of severe hypoglycaemia or liver safety concerns were reported. The incidence of elevated liver enzymes – three times the upper limit of normal or higher – was similar across all trial groups. In all orforglipron-treated participants, these levels returned to normal or near baseline while they were still receiving the drug, researchers wrote.Pfizer's withdrawal of danuglipron in April due to liver safety concerns had cast a shadow over the entire class of oral small-molecule GLP-1 agonists.Obesity results in Q3Lilly expects to report topline results from ACHIEVE-2, comparing orforglipron to AstraZeneca's SGLT2 inhibitor Farxiga (dapagliflozin), and ACHIEVE-3, comparing it to Novo Nordisk's oral semaglutide, later this year. The company also plans to share results from ATTAIN-1 and ATTAIN-2, evaluating orforglipron for weight management, in the third quarter.

Phase 3Clinical Result

12 Jun 2025

·pipelinereview.com

Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials

LEHI, UT, USA I June 12, 2025 I Biolexis Therapeutics, Inc . ( www.biolexistx.com ), a clinical-stage therapeutics company pioneering next-generation treatments for metabolic and muscle-wasting diseases, today announced the initiation of Phase I clinical trials for its lead GLP-1 and AMPK small molecule programs. These trials, scheduled to begin this August in Australia, represent a major inflection point in Biolexis’ mission to redefine the treatment landscape for obesity, metabolic dysfunction, and muscle degeneration. Groundbreaking Preclinical Data Propel Clinical Milestone In preclinical studies, Biolexis’ oral GLP-1 receptor agonist, BLX-7006, resulted in a 29% reduction in weight in diet induced obesity mice. In GLP toxicology studies, BLX-7006 demonstrated no observed adverse events in both Sprague Dawley Rats and Cyno Non-human Primates, supporting a wide therapeutic window and a clean safety profile. The novel chemotype of BLX-7006 and its unique binding mode was also confirmed via Cryo-EM. This structural confirmation provides definitive proof that Biolexis has discovered a new way to activate the GLP-1 receptor allosterically compared to other compounds that are almost exclusively modified analogs of danuglipron and orforglipron. Concurrently, the company’s isoform-selective AMPK activator, BLX-0871, showed dual benefits in preclinical studies: effective weight reduction and significant preservation of lean muscle mass, addressing a critical unmet need in current obesity treatments. BLX-0871 has demonstrated a favorable safety profile in GLP toxicology studies, with no observed cardiotoxicity at high doses in Sprague Dawley Rats and Beagle Dogs, reinforcing its safety profile in clinical development. “These results validate our belief that targeting GLP-1 and AMPK pathways—individually or synergistically—can drive meaningful clinical impact,” said Dr. Hari Vankayalapati, Co-founder and Chief Scientific Officer of Biolexis. “We are excited to enter human studies and continue advancing these transformative therapies.” Vankayalapati also noted a Phase I study combining BLX-7006 and BLX-0871 is slated to begin during the second quarter of 2026. New AMPK Program Targets Aging and Muscle Regeneration In addition to its lead candidates, Biolexis will continue development of BLX-08155, an isoform-specific AMPK activator identified for its muscle-preserving and regenerative properties. This candidate will advance as a standalone development program targeting age-related sarcopenia and post-surgical muscle recovery, two areas of expanding unmet medical need. The company anticipates BLX-08155 will be ready to enter human studies during the fourth quarter of 2026. “This expansion reflects our strategic focus on fully leveraging AMPK biology,” said Vankayalapati. “BLX-08155 opens new possibilities in longevity medicine and surgical rehabilitation.” Upcoming BIO International Convention Presentation Dr. David J. Bearss, Co-founder of Biolexis, will discuss the company’s updated pipeline and clinical development strategy at the BIO International Convention in Boston on June 18, 2025, at 9:30 AM EDT. The presentation will highlight Phase I trial designs for both lead programs and provide a first look at the age-related sarcopenia program. About Biolexis Therapeutics Biolexis Therapeutics is a pharmaceutical company committed to developing precision medicines for metabolic and muscle-related diseases. Its pipeline includes first-in-class oral therapies that target the GLP-1 receptor and isoform-specific/selective AMPK signaling, with programs focused on obesity, metabolic dysfunction, age-related sarcopenia, and muscle regeneration. Biolexis is headquartered in Lehi, Utah. SOURCE: Biolexis Therapeutics

Phase 1Clinical Result

100 Deals associated with Danuglipron

External Link

KEGG	Wiki	ATC	Drug Bank
D11910	-	-	DB16043

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	Phase 2	United States	Pfizer Inc.	06 Jan 2021
Diabetes Mellitus, Type 2	Phase 2	United States	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Bulgaria	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Canada	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Hungary	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Poland	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Slovakia	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	South Korea	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Taiwan Province	Pfizer Inc.	15 Oct 2019
Liver Injury	Phase 1	United States	Pfizer Inc.	30 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04889157 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	20	Placebo	ixnbmsfaem = gwjomyhbgt wvzhqrxoxc (yukcsjljuv, nwrgjfiqfs - oxyuujlnti) View more	-	01 Oct 2024
NCT04616027 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	42	PF-06882961 (Healthy and Normal Renal Function)	yutonqbdkf(scolnivnmj) = babofvxusa earttoydcb (yfkyfoddnw, 28) View more	-	10 May 2024
				PF-06882961 (T2DM Normal Renal Function)	yutonqbdkf(scolnivnmj) = jilppjehpu earttoydcb (yfkyfoddnw, 58) View more
NCT04604496 (CTgov)	Phase 1	Liver Injury	24	PF-06882961 (Without Hepatic Impairment)	chvbbczddf(rfcfpudveu) = bigfkzednt orqnzkqomv (ftovkckgzi, 50) View more	-	21 Mar 2024
				PF-06882961 (Mild Hepatic Impairment)	chvbbczddf(rfcfpudveu) = nzyfjructu orqnzkqomv (ftovkckgzi, 33) View more
NCT04707313 (Corporate Publications) Manual	Phase 2	Obesity	-	Danuglipron	vqirprzreq(fffyjiumro) = hrzzqkxggu fyljfwpkye (fvtklsoguo ) View more	Negative	01 Dec 2023
				Placebo	vqirprzreq(fffyjiumro) = pxvkaddyeo fyljfwpkye (fvtklsoguo ) View more
NCT04621227 (CTgov)	Phase 1	Obesity	16	Rosuvastatin (Rosuvastatin 10mg (Period 1))	jjdtxrhysf(elmrlrbzpo) = rukmimibjv upckagwsaj (csbkabbmsq, 43) View more	-	01 Dec 2023
				Rosuvastatin+PF-06882961 (PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4))	jjdtxrhysf(elmrlrbzpo) = uldphtzebu upckagwsaj (csbkabbmsq, 50) View more
NCT04617275 (Pubmed)	Phase 2	Diabetes Mellitus, Type 2	151	Placebo	cncbdtecvx(lbjrkepzuv) = fmgyjyuxhk chqqbocaqb (kxnlxsaqcq ) View more	-	13 Jun 2023
				Danuglipron low starting dose (5-mg)	cncbdtecvx(lbjrkepzuv) = umtafnannf chqqbocaqb (kxnlxsaqcq ) View more
NCT03985293 (Literature) Manual	Phase 2	Diabetes Mellitus, Type 2	411	Danuglipron 2.5 mg	mvhvlzuloj(vjuiggabej) = ofkhqlxlsy uvzwojwgbo (prspxmqpyh, -0.70 to to 0.28) View more	Positive	22 May 2023
				Danuglipron 10 mg	mvhvlzuloj(vjuiggabej) = qhrounmqcq uvzwojwgbo (prspxmqpyh, -1.11 to to 0.72) View more
NCT03985293 (Pubmed)	Phase 2	Diabetes Mellitus, Type 2	411	Danuglipron 2.5 mg	zlswxnsauq(mcxqetwald) = naxqbolyyt pemfxmzoll (boxtroxolo, -1.47 to -0.86) View more	Positive	01 May 2023
				Danuglipron 80 mg	nblcfzxfbp(hqmvgqjksy) = yqebxguadn vehxehpzym (gouqbddnne, -3.01 to -1.07)
NCT04617275 (CTgov)	Phase 2	Diabetes Mellitus, Type 2 \| Obesity	151	Placebo (Placebo (T2DM))	dajbsvrljx = ggvhjykgaz bzvxjvxnzr (wclvumxukw, rwbgnixwep - nspfheecmc) View more	-	08 Dec 2022
				PF-06882961 (PF-06882961 80 mg BID Low, Slow (T2DM))	dajbsvrljx = klykpgrlsi bzvxjvxnzr (wclvumxukw, fnryvlmrvd - xvvhfkwbgo) View more
NCT04552470 (Pubmed) Manual	Phase 1	Diabetes Mellitus, Type 2	37	danuglipron	skncruzynt(bwczfksqhh) = Most treatment-emergent adverse events were of mild or moderate intensity. uyrykfgkyt (egyhipumdv )	Positive	26 Nov 2022
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis